Tolvaptan
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tolvaptan and local guidelines before prescribing.
Vasopressin antagonist
Mechanism
Vasopressin V2 antagonist (aquaretic).
Uses
SIADH hyponatraemia (specialist), ADPKD.
Dosing
- Tolvaptan (a vasopressin V2 receptor antagonist, specialist). Start in hospital at a low dose (7.5–15 mg), with frequent sodium checks because of the risk of overcorrection. Avoid in liver disease (hepatotoxicity).
Endocrinology: Sodium and Water disorders - Tolvaptan SIADH | Specialist only. Start in hospital at 7.5–15 mg daily; frequent sodium checks; avoid in liver disease.
Endocrinology: Sodium and Water disorders - Tolvaptan SIADH (specialist) | Start 15 mg once daily in hospital, with close sodium monitoring. Avoid rapid correction; liver toxicity.
Endocrinology: Pituitary Disease
Side effects
Thirst, polyuria, hepatotoxicity, rapid sodium correction risk.
Interactions
CYP3A4 inhibitors; diuretics.
Contraindications and cautions
Hypovolaemia, hypernatraemia, liver disease
Monitoring
Sodium, LFT
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Do not correct sodium faster than 8–10 mmol/L per day; hospital initiation.
More from the textbook: uses, cautions and other points
- Tolvaptan | V2 antagonist for SIADH; start in hospital; avoid rapid sodium rise; liver toxicity.
Endocrine: Anatomy Physiology and Pharmacology - Autosomal dominant polycystic kidney disease (ADPKD - PKD1 about 85%, more severe; PKD2) - enlarging cysts, hypertension, haematuria, pain, CKD (often needing dialysis by middle age with PKD1), liver cysts , berry aneurysms (screen if family history of SAH), mitral valve prolapse; tolvaptan slows growth in selected patients.
Renal: Anatomy, Physiology and Pharmacology - Tolvaptan - slows kidney enlargement in rapidly progressing ADPKD (specialist; liver monitoring, thirst and polyuria).
Renal: Anatomy, Physiology and Pharmacology - Tolvaptan | ADPKD (and SIADH); liver toxicity; thirst.
Renal: Anatomy, Physiology and Pharmacology - Consider tolvaptan (NICE TA358) with LFT monitoring; warn about polyuria.
Renal: Tubular Inherited Stones - Treat the cancer; fluid restriction; tolvaptan or urea.
Respiratory: Lung Cancer - Fluid restriction; oral urea or tolvaptan if it fails.
Endocrinology: Sodium and Water disorders - Oral urea or tolvaptan in selected patients (specialist).
Endocrinology: Pituitary Disease
Where it is discussed in the book
- Respiratory: Lung Cancer (1 mention)
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Sodium and Water disorders (3 mentions)
- Endocrinology: Pituitary Disease (2 mentions)
- Renal: Anatomy, Physiology and Pharmacology (4 mentions)
- Renal: Tubular Inherited Stones (4 mentions)
- Acute Medicine: Electrolytes, acid–base, AKI and metabolic emergencies (1 mention)
- Clinical Genetics: Single-gene, repeat-expansion and mitochondrial disorders (3 mentions)
- Integrated respiratory chapter (1 mention)